Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120873088> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3120873088 endingPage "130" @default.
- W3120873088 startingPage "130" @default.
- W3120873088 abstract "Background and Aim: Filgotinib (FIL), an oral, potent, selective JAK‐1 inhibitor, provided statistically significant and clinically meaningful improvement in rheumatoid arthritis (RA) signs and symptoms, physical function, radiographic progression, and quality of life in four Phase III (FINCH 1–4; NCT02889796, NCT02873936, NCT02886728, NCT03025308) and three Phase II (DARWIN 1–3; NCT01668641, NCT01894516, NCT02065700) trials in patients with RA. We aimed to integrate data from these seven clinical trials of FIL to assess its long‐term safety in patients with RA.Methods: Treatment‐emergent adverse events (TEAEs) from the FIL clinical program were integrated and presented for patients receiving FIL 200 mg or FIL 100 mg once daily (including patients who transitioned to FIL from placebo [PBO], methotrexate [MTX], adalimumab [ADA], or another dose of FIL), as well as patients receiving PBO, MTX, and ADA. Patients could contribute to more than one treatment group. Exposure‐adjusted incidence rates (EAIRs) per 100 patient‐years were calculated for adverse events (AEs) of interest per treatment. Incidence was total number of patients with events, and patient‐year exposure was time between first and last doses. Major adverse cardiovascular events (MACEs) and venous thromboembolism (VTE) were centrally adjudicated by an independent committee.Results: Across seven trials, 4057 patients with RA (2227 patients taking FIL 200 mg, 1600 patients taking FIL 100 mg) received more than one dose of treatment for a total 5493 patient‐years of exposure (3079.2 patient‐years for FIL 200 mg, 1465.3 patient‐years for FIL 100 mg) (Table 1). EAIRs of serious AEs and TEAEs leading to death in patients taking FIL were comparable with those with PBO, ADA, or MTX, with no dose‐dependent effect (Table 1). The EAIRs for herpes zoster were low overall but numerically slightly higher for FIL relative to PBO and ADA and similar to MTX. Serious infection EAIRs were comparable between patients receiving FIL 100 mg and ADA and numerically slightly lower for FIL 200 mg and MTX. Rates of opportunistic infections (including active tuberculosis) were low overall; EAIRs for FIL doses were comparable with those for placebo and numerically lower than ADA or MTX. Rates of MACE and VTE were numerically lower for FIL relative to PBO. Malignancies were rare overall, and rates were low in patients receiving FIL (Table 1). Rates of adjudicated VTE were numerically lower with both FIL doses than with MTX, ADA, or PBO." @default.
- W3120873088 created "2021-01-18" @default.
- W3120873088 creator A5003819213 @default.
- W3120873088 creator A5006070255 @default.
- W3120873088 creator A5011826741 @default.
- W3120873088 creator A5026328229 @default.
- W3120873088 creator A5027087975 @default.
- W3120873088 creator A5038275921 @default.
- W3120873088 creator A5038349879 @default.
- W3120873088 creator A5040902484 @default.
- W3120873088 creator A5046562616 @default.
- W3120873088 creator A5051779319 @default.
- W3120873088 creator A5055202702 @default.
- W3120873088 creator A5057491763 @default.
- W3120873088 creator A5076851275 @default.
- W3120873088 creator A5089413595 @default.
- W3120873088 creator A5091885715 @default.
- W3120873088 date "2020-01-01" @default.
- W3120873088 modified "2023-09-26" @default.
- W3120873088 title "Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from seven clinical trials" @default.
- W3120873088 hasPublicationYear "2020" @default.
- W3120873088 type Work @default.
- W3120873088 sameAs 3120873088 @default.
- W3120873088 citedByCount "0" @default.
- W3120873088 crossrefType "journal-article" @default.
- W3120873088 hasAuthorship W3120873088A5003819213 @default.
- W3120873088 hasAuthorship W3120873088A5006070255 @default.
- W3120873088 hasAuthorship W3120873088A5011826741 @default.
- W3120873088 hasAuthorship W3120873088A5026328229 @default.
- W3120873088 hasAuthorship W3120873088A5027087975 @default.
- W3120873088 hasAuthorship W3120873088A5038275921 @default.
- W3120873088 hasAuthorship W3120873088A5038349879 @default.
- W3120873088 hasAuthorship W3120873088A5040902484 @default.
- W3120873088 hasAuthorship W3120873088A5046562616 @default.
- W3120873088 hasAuthorship W3120873088A5051779319 @default.
- W3120873088 hasAuthorship W3120873088A5055202702 @default.
- W3120873088 hasAuthorship W3120873088A5057491763 @default.
- W3120873088 hasAuthorship W3120873088A5076851275 @default.
- W3120873088 hasAuthorship W3120873088A5089413595 @default.
- W3120873088 hasAuthorship W3120873088A5091885715 @default.
- W3120873088 hasConcept C120665830 @default.
- W3120873088 hasConcept C121332964 @default.
- W3120873088 hasConcept C126322002 @default.
- W3120873088 hasConcept C141071460 @default.
- W3120873088 hasConcept C142724271 @default.
- W3120873088 hasConcept C197934379 @default.
- W3120873088 hasConcept C199475168 @default.
- W3120873088 hasConcept C204787440 @default.
- W3120873088 hasConcept C27081682 @default.
- W3120873088 hasConcept C2777575956 @default.
- W3120873088 hasConcept C2780132546 @default.
- W3120873088 hasConcept C2781059491 @default.
- W3120873088 hasConcept C535046627 @default.
- W3120873088 hasConcept C57658597 @default.
- W3120873088 hasConcept C61511704 @default.
- W3120873088 hasConcept C71924100 @default.
- W3120873088 hasConceptScore W3120873088C120665830 @default.
- W3120873088 hasConceptScore W3120873088C121332964 @default.
- W3120873088 hasConceptScore W3120873088C126322002 @default.
- W3120873088 hasConceptScore W3120873088C141071460 @default.
- W3120873088 hasConceptScore W3120873088C142724271 @default.
- W3120873088 hasConceptScore W3120873088C197934379 @default.
- W3120873088 hasConceptScore W3120873088C199475168 @default.
- W3120873088 hasConceptScore W3120873088C204787440 @default.
- W3120873088 hasConceptScore W3120873088C27081682 @default.
- W3120873088 hasConceptScore W3120873088C2777575956 @default.
- W3120873088 hasConceptScore W3120873088C2780132546 @default.
- W3120873088 hasConceptScore W3120873088C2781059491 @default.
- W3120873088 hasConceptScore W3120873088C535046627 @default.
- W3120873088 hasConceptScore W3120873088C57658597 @default.
- W3120873088 hasConceptScore W3120873088C61511704 @default.
- W3120873088 hasConceptScore W3120873088C71924100 @default.
- W3120873088 hasLocation W31208730881 @default.
- W3120873088 hasOpenAccess W3120873088 @default.
- W3120873088 hasPrimaryLocation W31208730881 @default.
- W3120873088 hasVolume "35" @default.
- W3120873088 isParatext "false" @default.
- W3120873088 isRetracted "false" @default.
- W3120873088 magId "3120873088" @default.
- W3120873088 workType "article" @default.